WO2002007693A1 - Improved diagnostic method for detecting dysplastic epithelial tissue - Google Patents

Improved diagnostic method for detecting dysplastic epithelial tissue Download PDF

Info

Publication number
WO2002007693A1
WO2002007693A1 PCT/US2000/020017 US0020017W WO0207693A1 WO 2002007693 A1 WO2002007693 A1 WO 2002007693A1 US 0020017 W US0020017 W US 0020017W WO 0207693 A1 WO0207693 A1 WO 0207693A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
cancerous
precancerous
diagnostic method
epithelial tissue
Prior art date
Application number
PCT/US2000/020017
Other languages
French (fr)
Inventor
Douglas D. Burkett
Original Assignee
Zila, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002513430A priority Critical patent/JP2004504615A/en
Application filed by Zila, Inc. filed Critical Zila, Inc.
Priority to NZ517637A priority patent/NZ517637A/en
Priority to PCT/US2000/020017 priority patent/WO2002007693A1/en
Priority to EP00950579A priority patent/EP1301164A4/en
Priority to IL14842900A priority patent/IL148429A0/en
Priority to BR0014130-5A priority patent/BR0014130A/en
Priority to CN00813014A priority patent/CN1374855A/en
Priority to AU18402/01A priority patent/AU785490B2/en
Priority to US10/069,836 priority patent/US6967015B1/en
Priority to MXPA02002644A priority patent/MXPA02002644A/en
Priority to TW089116023A priority patent/TWI281412B/en
Publication of WO2002007693A1 publication Critical patent/WO2002007693A1/en
Priority to NO20021355A priority patent/NO20021355L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0071—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form solution, solute
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Definitions

  • This invention relates to an improved diagnostic method for in vivo detection of dysplastic epithelial tissue.
  • the invention is an improved diagnostic method for detecting and/or delineating cancerous or precancerous epithelial tissue, with a reduced rate of false positives.
  • the false positive rate of diagnostic methods that involve topical application of a dye that selectively stains cancerous and precancerous epithelial tissue is markedly reduced.
  • cationic supravital dyes have the capability of selectively staining cancerous and precancerous cells of epithelial tissue, as well as cells that are abnormal due to dysplasia, hyperplasia, tumorigenesis and other active surface lesions.
  • such dyes are disclosed in U.S. Patents Nos. 4,321,251 to Mashberg, 5,372,801 to Tucci, et al . r 5,882,627 to Pomerantz, and the pending International
  • the mechanism of such selective staining has been shown to involve absorption or entry of the marking agent molecule into the mitochondria of the cancerous or precancerous epithelial cells.
  • This selective staining of the mitochondria of cancerous tissue is apparently due to the higher electrical potential (negative charge on the inside of the membrane of cancerous mitochondrial cells as compared to normal cells.
  • the mitochondrial marking agent also temporarily stains nearby non-cancerous tissue, it is released much more quickly from the normal tissue than from the mitochondria of the cancerous tissue.
  • diagnosis of cancer is based on the continued retention of the dye in the cancerous tissue after it is autogenously released from the normal tissue.
  • the temporary, less pronounced tendency of these dyes to stain normal tissue is due to binding of the dye with components of the extracellular matrix ("ECM") of epithelial tissue. Whereas the dye actually enters the mitochondria of cancerous and precancerous cells, it is only temporarily bound to components of the ECM, particularly to fibronectin.
  • ECM extracellular matrix
  • Temporary binding of cationic dyes and other mitochondrial marking agents to ECM components may be due to one or more of a variety of mechanisms.
  • the mitochondrial marking agents may be temporarily bound to negatively charged ECM proteins by electrostatic attraction.
  • hydrophobic interactions may take place between the ECM proteins and heterocyclic portions of the marking agent which exclude water.
  • Other non-specific binding may occur by binding of various portions of the marking agent to ECM proteins that bind neutral charges.
  • Such temporary binding of mitochondrial marking agents to ECM proteins can occur even outside of the tight junctions between epithelial cells, e.g., on the surface of the epithelium, as well as between and beneath cancerous cells.
  • the undesired temporary binding of mitochondrial marking agents to ECM proteins can be largely prevented by pretreating the area of the epithelium to which the marking agent is to be applied with a non-toxic amphiphilic protein.
  • the amphiphilic protein enters the various binding mechanisms to the ECM proteins, thus temporarily disabling them from binding the mitochondial marking agent when it is later applied.
  • Such pretreatment of the epithelium with amphiphilic protein markedly reduces the occurrence of false positive reactions engendered by temporary binding of the mitochondrial marking agent to ECM proteins and the consequent appearance of "stained" areas on the normal epithelium which might be mistaken for cancerous or precancerous tissue.
  • amphiphilic protein to be applied as a pretreatment is not highly critical. All mucopolysaccharides are amphiphilic. However, for ease of handling and application, it is presently preferred to employ albumins (soluble in water) or globulins (soluble in dilute salt solutions). For example, serum albumin and milk proteins, such as casein, are effectively employed. Gluten proteins, such as wheat albumins and prolamins (soluble in aqueous alcohol) and glutenins (soluble in dilute acids and bases, detergents or reducing agents) are also effectively employed.
  • amphiphilic protein pre-treatment composition is prepared:
  • Flavor (IFF Raspberry IC563457) .5
  • a toluidine blue 0 (“TBO”) stain compositio5 is prepared, having the following composition
  • Flavor (IFF Raspberry IC563457) .20 Buffering Agent (sodium acetate trihydrate) 2.45 Preservative (hydrogen peroxide 30%) .41
  • Pre-rinse and post-rinse solutions of 1 wt% acetic acid in purified water, sodium benzoate preservative and raspberry flavor are prepared.
  • the patient is draped with a bib to protect clothing.
  • Expectoration is expected, so the patient is provided with a 10-oz. cup, which can be disposed of in an infectious waste container or the contents can be poured directly into the center drain of a sink to avoid staining the sink.
  • Environmental surfaces or objects which might be stained are draped or removed from the area.
  • a visual oral cancer examination is conducted, without using any instruments which might cause nicks or cuts of soft tissues. Notations are made of the appearance of soft tissues and teeth.
  • the patient rinses the oral cavity with approximately 15 ml of the of the pre-rinse solution for approximately 20 seconds and expectorates, to remove excess saliva and provide a consistent oral environment. This step is then repeated with additional pre-rinse solution.
  • the patient then rinses and gargles with approximately 50 ml of the protein pretreatment composition for approximately 30 seconds and expectorates. This step is then repeated, except that the patient retains the protein pretreatment composition within the mouth for approximately two minutes, then expectorates.
  • the patient then rinses with 15 ml of the post rinse solution and expectorates. This step is then repeated.
  • the patient then rinses and gargles with water for 20 seconds and expectorates. This step is then repeated.
  • Visual observations of the oral cavity are then made, using appropriate soft-tissue examination techniques, including retraction, well-balanced lighting and magnification, if necessary.
  • the location, size, morphology, color and surface characteristics of suspect lesions, that have retained blue coloration are made and recorded.
  • Example 1 The procedures of Examples 1-4 are repeated except that the protein pre-treat ent solution of Example 1 consists of globulins, casein, gluten albumin, wheat prolamin and glutenins in suitable pharmacologically acceptable solvents, with suitable flavorings. Equivalent results are obtained.

Abstract

A method of intraoral toluidine blue staining is disclosed where the pre-rinse composition contains amphiphilic protein, such as albumin, which binds to extracellular matrix components such as fibronectin. In this way, the staining is more specific to precancerous and cancerous cells.

Description

IMPROVED DIAGNOSTIC METHOD FOR DETECTING DYSPLASTIC EPITHELIAL TISSUE
This invention relates to an improved diagnostic method for in vivo detection of dysplastic epithelial tissue.
In a more particular respect, the invention is an improved diagnostic method for detecting and/or delineating cancerous or precancerous epithelial tissue, with a reduced rate of false positives.
According to another aspect of the invention, the false positive rate of diagnostic methods that involve topical application of a dye that selectively stains cancerous and precancerous epithelial tissue is markedly reduced.
These and other, further and more specific aspects of the invention will be apparent to those skilled in the art from the following description thereof.
It is known that various cationic supravital dyes have the capability of selectively staining cancerous and precancerous cells of epithelial tissue, as well as cells that are abnormal due to dysplasia, hyperplasia, tumorigenesis and other active surface lesions.. For example, such dyes are disclosed in U.S. Patents Nos. 4,321,251 to Mashberg, 5,372,801 to Tucci, et al . r 5,882,627 to Pomerantz, and the pending International
Application of Bernal et al . , PCT/USOO/05387. Also, see Chenz, Chinese Journal of Stomatology (27 : 44-47) (1992) and Filurin, Stomatologiia (Russian) (72:44-47) ( 1993) . Other dyes that are similarly useful include rhodamine, alcian blue, malachite green, phenosafranin, acriflavine, pyronine Y, toluylene blue, and brilliant green. "Non- dye" compounds that are similarly useful include peonidin, oxythiamine, tiemonium iodide, elliptinium acetate and furazolium chloride.
The mechanism of such selective staining has been shown to involve absorption or entry of the marking agent molecule into the mitochondria of the cancerous or precancerous epithelial cells. This selective staining of the mitochondria of cancerous tissue is apparently due to the higher electrical potential (negative charge on the inside of the membrane of cancerous mitochondrial cells as compared to normal cells. Although the mitochondrial marking agent also temporarily stains nearby non-cancerous tissue, it is released much more quickly from the normal tissue than from the mitochondria of the cancerous tissue. Thus the diagnosis of cancer is based on the continued retention of the dye in the cancerous tissue after it is autogenously released from the normal tissue. Proper selection of the elapsed time between application of the dye and the diagnostic observation of the tissue, permits the diagnostician to detect and selectively delineate cancerous or precancerous tissue sites on normal epithelial surfaces. This procedure permits identification of cancerous and potential cancerous sites with a high degree of accuracy, i.e., with a very low incidence of false negatives. However, because of differences in the tissues between patients and other variables such as skill of the diagnostician, etc., this diagnostic technique may also yield false positive results.
While false positives are much preferred over false negative results, it would, nevertheless, be highly desirable to reduce the rate of false positives, to avoid or reduce the necessity for invasive confirmatory testing and to avoid unnecessarily upsetting the patient.
To attempt to reduce the rate of false positives, it has been proposed to repeat the procedure after approximately two weeks, which gives time for healing of non-cancerous lesions or wounds which apparently tend to accumulate and retain the dye longer than normal tissue, even though they are not cancerous or precancerous. Of course, this repetition does prevent a number of false positives. However, the potential still remains for false positive due to other causes.
The temporary, less pronounced tendency of these dyes to stain normal tissue is due to binding of the dye with components of the extracellular matrix ("ECM") of epithelial tissue. Whereas the dye actually enters the mitochondria of cancerous and precancerous cells, it is only temporarily bound to components of the ECM, particularly to fibronectin.
Temporary binding of cationic dyes and other mitochondrial marking agents to ECM components may be due to one or more of a variety of mechanisms. Thus the mitochondrial marking agents may be temporarily bound to negatively charged ECM proteins by electrostatic attraction. Furthermore, hydrophobic interactions may take place between the ECM proteins and heterocyclic portions of the marking agent which exclude water. Other non-specific binding may occur by binding of various portions of the marking agent to ECM proteins that bind neutral charges. Such temporary binding of mitochondrial marking agents to ECM proteins can occur even outside of the tight junctions between epithelial cells, e.g., on the surface of the epithelium, as well as between and beneath cancerous cells.
The undesired temporary binding of mitochondrial marking agents to ECM proteins can be largely prevented by pretreating the area of the epithelium to which the marking agent is to be applied with a non-toxic amphiphilic protein. The amphiphilic protein enters the various binding mechanisms to the ECM proteins, thus temporarily disabling them from binding the mitochondial marking agent when it is later applied. Such pretreatment of the epithelium with amphiphilic protein markedly reduces the occurrence of false positive reactions engendered by temporary binding of the mitochondrial marking agent to ECM proteins and the consequent appearance of "stained" areas on the normal epithelium which might be mistaken for cancerous or precancerous tissue.
The exact nature of the amphiphilic protein to be applied as a pretreatment is not highly critical. All mucopolysaccharides are amphiphilic. However, for ease of handling and application, it is presently preferred to employ albumins (soluble in water) or globulins (soluble in dilute salt solutions). For example, serum albumin and milk proteins, such as casein, are effectively employed. Gluten proteins, such as wheat albumins and prolamins (soluble in aqueous alcohol) and glutenins (soluble in dilute acids and bases, detergents or reducing agents) are also effectively employed.
The following examples illustrate the presently preferred practice of the invention. Those skilled in the art will understand and appreciate modifications of this procedure that can be made without departing from the basic concept of the invention. Consequently, these examples are not to taken as limiting the scope of the invention, which is defined only by the appended claim. EXAMPLE 1
Preparation of Pre-Treatment Composition
The following amphiphilic protein pre-treatment composition is prepared:
Component Weiqht %
Serum albumin 30
Sterile water 68. 5
Flavor (IFF Raspberry IC563457) .5
Preservative (sodium benzoate) 1 . 0
EXAMPLE 2
Preparation of TBO Stain Composition
A toluidine blue 0 ("TBO") stain compositio5 is prepared, having the following composition
Component Weiqht
TBO 1.00
Flavor (IFF Raspberry IC563457) .20 Buffering Agent (sodium acetate trihydrate) 2.45 Preservative (hydrogen peroxide 30%) .41
Acetic acid 4.61
Ethyl alcohol 7.48
Water 83.85 EXAMPLE 3 Preparation of pre-rinse and Post-rinse Solutions
Pre-rinse and post-rinse solutions of 1 wt% acetic acid in purified water, sodium benzoate preservative and raspberry flavor are prepared.
EXAMPLE 4 Clinical Protocol
The patient is draped with a bib to protect clothing. Expectoration is expected, so the patient is provided with a 10-oz. cup, which can be disposed of in an infectious waste container or the contents can be poured directly into the center drain of a sink to avoid staining the sink. Environmental surfaces or objects which might be stained are draped or removed from the area.
A visual oral cancer examination is conducted, without using any instruments which might cause nicks or cuts of soft tissues. Notations are made of the appearance of soft tissues and teeth. The patient rinses the oral cavity with approximately 15 ml of the of the pre-rinse solution for approximately 20 seconds and expectorates, to remove excess saliva and provide a consistent oral environment. This step is then repeated with additional pre-rinse solution.
The patient then rinses and gargles with water for approximately 20 seconds and expectorates.
The patient then rinses and gargles with approximately 50 ml of the protein pretreatment composition for approximately 30 seconds and expectorates. This step is then repeated, except that the patient retains the protein pretreatment composition within the mouth for approximately two minutes, then expectorates.
The patient then rinses and gargles with 30 ml. of the TBO solution for one minute and expectorates.
The patient then rinses with 15 ml of the post rinse solution and expectorates. This step is then repeated. The patient then rinses and gargles with water for 20 seconds and expectorates. This step is then repeated.
Visual observations of the oral cavity are then made, using appropriate soft-tissue examination techniques, including retraction, well-balanced lighting and magnification, if necessary. The location, size, morphology, color and surface characteristics of suspect lesions, that have retained blue coloration are made and recorded.
Specimens of any tissues that have retained blue coloration are obtained and subjected to normal cancer- detection histological procedures. No "false positives" specimens are noted.
EXAMPLE 5 Use of Other Proteins
The procedures of Examples 1-4 are repeated except that the protein pre-treat ent solution of Example 1 consists of globulins, casein, gluten albumin, wheat prolamin and glutenins in suitable pharmacologically acceptable solvents, with suitable flavorings. Equivalent results are obtained.
EXAMPLE 6 Use of Other Mitochondrial Marking Dyes
The procedures of Examples 1-5 are repeated except that the staining dyes employed are Azure B, Azure C,
Brilliant Cresyl Blue, Rhodamine, Alcian Blue, Malachite Green, Phenosafranin, Acriflavine, Pyronine Y, Toluylene Blue, Brilliant Green, Peonidin, Oxythiamine, tiemonium iodide, elliptinium acetate and furazolium chloride. Equivalent results are obtained.
Having described my invention in such terms as to enable those skilled in the art to understand and practice it and, having identified the presently preferred embodiments thereof, I CLAIM:

Claims

1. In a diagnostic method for detecting dysplastic epitheleal tissue, which includes the step of
topically applying a mitochondrial marking agent to the locus of suspect tissue which selectively stains cancerous and precancerous cells,
the method of decreasing the rate of false positives of said method comprising inhibiting the marking of extracellular matrix components by said stain, by applying a protein to said locus, prior to application of said stain.
2. The use of an amphiphilic protein to pretreat epithelial tissue before application of a mitochondrial marking agent for detecting cancerous or precancerous tissue, to bind ECM proteins and reduce the likelihood of a false positive indication.
PCT/US2000/020017 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue WO2002007693A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR0014130-5A BR0014130A (en) 2000-07-20 2000-07-20 Use of a mitochondrial marking agent to detect dysplastic epithelial tissue and use of an amphiphilic protein
NZ517637A NZ517637A (en) 2000-07-20 2000-07-20 Diagnostic method for detecting dysplastic epithelial tissue using a prerinse composition containing a protein which binds to the extracellular matrix components
PCT/US2000/020017 WO2002007693A1 (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue
EP00950579A EP1301164A4 (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue
IL14842900A IL148429A0 (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue
JP2002513430A JP2004504615A (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue
CN00813014A CN1374855A (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue
MXPA02002644A MXPA02002644A (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue.
US10/069,836 US6967015B1 (en) 2000-07-20 2000-07-20 Diagnostic method for detecting dysplastic epithelial tissue
AU18402/01A AU785490B2 (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue
TW089116023A TWI281412B (en) 2000-07-20 2000-08-09 Improved method for detecting dysplastic epithelial tissue
NO20021355A NO20021355L (en) 2000-07-20 2002-03-19 Improved diagnostic method for the detection of dysplastic epithelial tissue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/020017 WO2002007693A1 (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue

Publications (1)

Publication Number Publication Date
WO2002007693A1 true WO2002007693A1 (en) 2002-01-31

Family

ID=21741605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020017 WO2002007693A1 (en) 2000-07-20 2000-07-20 Improved diagnostic method for detecting dysplastic epithelial tissue

Country Status (10)

Country Link
US (1) US6967015B1 (en)
EP (1) EP1301164A4 (en)
JP (1) JP2004504615A (en)
CN (1) CN1374855A (en)
AU (1) AU785490B2 (en)
IL (1) IL148429A0 (en)
MX (1) MXPA02002644A (en)
NO (1) NO20021355L (en)
TW (1) TWI281412B (en)
WO (1) WO2002007693A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214101A1 (en) * 2000-02-28 2002-06-19 Zila, Inc. Method for detecting and killing epithelial cancer cells
WO2004035091A1 (en) * 2002-10-14 2004-04-29 Fluoron Gmbh Production of a dye for colouring cells in the human or animal body

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036149A1 (en) * 2004-09-28 2006-04-06 Zila Pharmaceuticals, Inc. Methods for detecting abnormal epithelial tissue
AU2004324049A1 (en) * 2004-09-30 2006-04-20 Zila Biotechnology, Inc. Light-directed method for detecting and aiding further evaluation of abnormal mucosal tissue
AU2008350867B2 (en) 2007-09-29 2014-08-28 Timothy James Williams Composition and method to modify sperm function and increase male gender ratio in mammals
ES2915263T3 (en) 2011-06-17 2022-06-21 Roche Diagnostics Hematology Inc Solution and procedure for the histoprocessing of biological samples
CN105510321A (en) * 2011-12-29 2016-04-20 闫文广 Detection agent composition for epithelial tissue tumor cells and preparing method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321251A (en) * 1979-12-19 1982-03-23 The United States Of America As Represented By The Department Of Health And Human Services Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse
US5882627A (en) * 1996-01-16 1999-03-16 Zila Pharmaceuticals, Inc. Methods and compositions for in-vivo detection of oral cancers precancerous conditions
US6086852A (en) * 1997-11-13 2000-07-11 Zila, Inc. In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229471T2 (en) * 1991-10-31 1999-11-25 Zila Inc BIOLOGICAL DYE COMPOSITION, PROCESS FOR ITS PRODUCTION AND USE FOR MARKING THE OUTLINE OF EPITHELIC CARSINOMAS
JPH07507812A (en) * 1993-01-14 1995-08-31 ジラ・インコーポレーテッド Screening method for epithelial cancer and kit for the screening
JPH08196272A (en) * 1995-01-23 1996-08-06 Asahi Chem Ind Co Ltd Hybridoma 29d38
US5925552A (en) * 1996-04-25 1999-07-20 Medtronic, Inc. Method for attachment of biomolecules to medical devices surfaces
US6194573B1 (en) * 1997-11-13 2001-02-27 Zila, Inc. Process for manufacture of in vivo stain composition
AU3102699A (en) * 1998-03-19 1999-10-11 Board Of Regents, The University Of Texas System Fiber-optic confocal imaging apparatus and methods of use
US6649144B1 (en) * 2000-02-28 2003-11-18 Zila, Inc. Method for detecting and killing epithelial cancer cells
GR1004180B (en) * 2000-03-28 2003-03-11 ����������� ����� ��������� (����) Method and system for characterization and mapping of tissue lesions
US6376525B1 (en) * 2000-09-15 2002-04-23 Qingzhong Kong Method and composition for treating cancer using cellular organelle crystallizing agents
CA2392213A1 (en) * 2000-09-26 2002-04-04 Zila, Inc. Method for early prediction of the onset of invasive cancer
US20040146919A1 (en) * 2002-05-18 2004-07-29 Burkett Douglas D. Method for early prediction of the onset of invasive cancer
WO2003072826A1 (en) * 2001-12-14 2003-09-04 Zila, Inc. Stain-directed molecular analysis for cancer prognosis and diagnosis
US20030017158A1 (en) * 2002-03-08 2003-01-23 Bernal Samuel D. Method for detecting and killing epithelial cancer cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321251A (en) * 1979-12-19 1982-03-23 The United States Of America As Represented By The Department Of Health And Human Services Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse
US5882627A (en) * 1996-01-16 1999-03-16 Zila Pharmaceuticals, Inc. Methods and compositions for in-vivo detection of oral cancers precancerous conditions
US6086852A (en) * 1997-11-13 2000-07-11 Zila, Inc. In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1301164A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214101A1 (en) * 2000-02-28 2002-06-19 Zila, Inc. Method for detecting and killing epithelial cancer cells
EP1214101A4 (en) * 2000-02-28 2005-04-13 Zila Inc Method for detecting and killing epithelial cancer cells
WO2004035091A1 (en) * 2002-10-14 2004-04-29 Fluoron Gmbh Production of a dye for colouring cells in the human or animal body
DE10255601B4 (en) 2002-10-14 2012-10-25 Fluoron Gmbh Use of a triphenylmethane dye for the manufacture of a stain for retinal and vitreous surgery
DE10255601C5 (en) * 2002-10-14 2017-10-19 Fluoron Gmbh Use of a triphenylmethane dye for the manufacture of a stain for retinal and vitreous surgery

Also Published As

Publication number Publication date
IL148429A0 (en) 2002-09-12
TWI281412B (en) 2007-05-21
EP1301164A4 (en) 2005-10-05
US6967015B1 (en) 2005-11-22
NO20021355D0 (en) 2002-03-19
CN1374855A (en) 2002-10-16
EP1301164A1 (en) 2003-04-16
NO20021355L (en) 2002-03-19
AU1840201A (en) 2002-02-05
AU785490B2 (en) 2007-11-15
MXPA02002644A (en) 2003-10-14
JP2004504615A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
EP0814847B1 (en) Methods and compositions for in-vivo detection of oral cancers and precancerous conditions
AU785490B2 (en) Improved diagnostic method for detecting dysplastic epithelial tissue
Bryan et al. Association of the human papillomavirus type 11 E1∧ E4 protein with cornified cell envelopes derived from infected genital epithelium
Joplin et al. Distribution of pyruvate dehydrogenase dihydrolipoamide acetyltransferase (PDC-E2) and another mitochondrial marker in salivary gland and biliary epithelium from patients with primary biliary cirrhosis
Çağlıkülekci et al. The effect of N-acetylcysteine (NAC) on liver and renal tissue inducible nitric oxide synthase (iNOS) and tissue lipid peroxidation in obstructive jaundice stimulated by lipopolysaccharide (LPS)
ES2819284T3 (en) Kit and method to detect porous dental hydroxyapatite
NZ517637A (en) Diagnostic method for detecting dysplastic epithelial tissue using a prerinse composition containing a protein which binds to the extracellular matrix components
JP2004502704A (en) Methylene blue diagnostic agent and diagnostic method for detecting epithelial cancer
WO2001064110A1 (en) Method for detecting and killing epithelial cancer cells
AU7987100A (en) Method for early prediction of the onset of invasive cancer
CA2266405A1 (en) Immunohistochemical staining composition
Pino Ultrastructural localization of lectin receptors on the surface of the rat retinal pigment epithelium. Decreased sensitivity of the avidin-biotin method due to cell surface charge.
Hume A reproducible technique combining tritiated thymidine autoradiography with immunodetection of bromodeoxyuridine for double labelling studies of cell proliferation in paraffin sections of tissues
Vavrina et al. Recurrent amyloid tumor of the parotid gland
AU784558B2 (en) Rhodamine diagnostic agent and diagnostic methods for detections of epithelial cancer
ES2248061T3 (en) IN VIVO STATION COMPOUNDS AND METHODS OF USE TO IDENTIFY DISPLASIC FABRICS.
US20040146919A1 (en) Method for early prediction of the onset of invasive cancer
JPS62135769A (en) Method and reagent for measuring ratio between protein and dna in cell
US20230176039A1 (en) A staining method for live-cell imaging
SU1635961A1 (en) Method for viable protoscoleces of echinococcus in vitro determination
NZ540800A (en) Methylene blue diagnostic agent and in vivo diagnostic methods for detection of epithelial cancer
CN113358615A (en) Application of melane and fluorescein sodium double staining method in living cell imaging
CN116519675A (en) Method for cleaning suspected contaminant and object, and method for controlling accuracy of cleaning operation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BR CH CN CZ HU IL IN JP KR MX NO NZ PL RO SG SK TR UA US ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 148429

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00252/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000950579

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 517637

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/002644

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2002 513430

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008130140

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 18402/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10069836

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000950579

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 517637

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517637

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2003131182

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2003131328

Country of ref document: RU

Kind code of ref document: A